Coagulation factor VIIa, recombinant

(NovoSeven®)

Coagulation factor VIIa, recombinant

Drug updated on 11/13/2023

Dosage FormLyophilized powder (intravenous: 1, 2, 5, or 8 mg)
Drug ClassCoagulation Factor
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For treatment of bleeding episodes and perioperative management in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and Glanzmann’s thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets.
  • For treatment of bleeding episodes and perioperative management in adults with acquired hemophilia.